Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics.

A D Roses1

  • 1GlaxoSmithKline, Five Moore Drive - 5616, Research Triangle Park, NC 27709, USA. adr69412@gsk.com

Human Molecular Genetics
|October 24, 2001
PubMed
Summary
This summary is machine-generated.

Pharmacogenetics uses genetic profiles to predict individual drug responses, improving safety and efficacy. This approach will enable personalized medicine within five years by identifying patients at risk of adverse events or those likely to benefit from specific treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polyallelic structural variants can provide accurate, highly informative genetic markers focused on diagnosis and therapeutic targets: Accuracy vs. Precision.

Clinical pharmacology and therapeutics·2015
Same author

Are APOE ɛ genotype and TOMM40 poly-T repeat length associations with cognitive ageing mediated by brain white matter tract integrity?

Translational psychiatry·2014
Same author

Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms.

Neuromuscular disorders : NMD·2013
Same author

Inhibition of α-ketoglutarate-and pyruvate dehydrogenase complexes in E. coli by a glutathione S-transferase containing a pathological length poly-Q domain: A possible role of energy deficit in neurological diseases associated with poly-Q expansions?

Age·2013
Same author

Using genetics to enable studies on the prevention of Alzheimer's disease.

Clinical pharmacology and therapeutics·2012
Same author

A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing.

Molecular psychiatry·2012
Same journal

Utrophin requires α-Syntrophin to maintain neuromuscular junction integrity in mdx mice.

Human molecular genetics·2026
Same journal

A novel gene ACTRT3 mutations induce sperm malformations and fertilization failure via Acrosomal ultrastructural defects.

Human molecular genetics·2026
Same journal

Nucleic acid-based therapeutic strategies for modulator-refractory cystic fibrosis-causing variants.

Human molecular genetics·2026
Same journal

Evidence that disruption of Discoidin domain receptor 2 contributes to palate malformations through effects on the extracellular matrix.

Human molecular genetics·2026
Same journal

Nicotinamide riboside prevents mitochondrial dysfunction in nemaline myopathy type 6.

Human molecular genetics·2026
Same journal

Retraction: Aqua-soluble DDQ reduces the levels of Dr1 and Ab and inhibits abnormal interactions between Ab and Dr1 and protects Alzheimer's disease neurons from Ab- and Dr1-induced mitochondrial and synaptic toxicities.

Human molecular genetics·2026
See all related articles

Area of Science:

  • Pharmacogenetics and Genomics
  • Molecular Biology
  • Clinical Pharmacology

Background:

  • Individual drug response variability is influenced by inherited genetic characteristics.
  • Drug metabolizing enzymes have been studied, evolving from chemical reactions to specific molecular polymorphisms.
  • Advances in whole-genome single-nucleotide polymorphism (SNP) mapping are revolutionizing pharmacogenetic research.

Purpose of the Study:

  • To explore the application of whole-genome SNP maps for creating patient genetic profiles.
  • To identify patients at higher risk for adverse events (AEs) or with increased likelihood of clinical efficacy.
  • To discuss the future integration of pharmacogenetic maps into drug registration and post-marketing surveillance.

Main Methods:

  • Utilizing high-density SNP maps in regions of genetic linkage to identify susceptibility genes.

Related Experiment Videos

  • Conducting whole-genome SNP mapping analyses to determine linkage disequilibrium (LD) profiles.
  • Developing SNP 'fingerprints' (SNP PRINTs(sm)) for patient risk stratification.

    • Main Results:

    • Proof-of-principle experiments confirm the feasibility of identifying disease genes using SNP maps.
    • Ongoing development of LD maps across diverse ethnic populations aims to reduce the number of SNPs needed per individual.
    • The creation of standardized pharmacogenetic maps is anticipated within the next five years.

    Conclusions:

    • Pharmacogenetic applications, including SNP profiling, promise safer, more effective, and cost-efficient medicines.
    • Standardized maps will enhance drug registration and post-marketing surveillance.
    • While immediate pharmacogenetic benefits are expected within 5 years, broader pharmacogenomic applications for new drug discovery will take 7-12 years.